title: Psoriatic arthritis.
abstract: Although there is still some controversy about the existence of psoriatic arthritis as a specific form of inflammatory arthritis associated with psoriasis, epidemiological, and clinical studies support the unique features of psoriatic arthritis. Because of lack of diagnostic or classification criteria, the disease has been thought of as uncommon. Over the past several decades, it has become clear that the disease leads to serious disability and even increased mortality. Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with the potential to control the inflammation and arrest the progression of joint damage.
authors.affiliation: Center for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario. dafna.gladman@utoronto.ca
authors.forename: Dafna D
authors.initials: DD
authors.lastname: Gladman
mesh_terms: D000068879:Adalimumab; D000077944:Alefacept; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000962:Antimalarials / Q000008:administration & dosage; D015535:Arthritis, Psoriatic / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D000068800:Etanercept; D006052:Gold Sodium Thiomalate / Q000008:administration & dosage; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D047888:Receptors, Tumor Necrosis Factor, Type I; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use; D053319:Tumor Necrosis Factor Decoy Receptors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000962:Antimalarials; D007074:Immunoglobulin G; D007555:Isoxazoles; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D011993:Recombinant Fusion Proteins; D053319:Tumor Necrosis Factor Decoy Receptors; D006052:Gold Sodium Thiomalate; C069521:recombinant human tumor necrosis factor-binding protein-1; D012460:Sulfasalazine; D016572:Cyclosporine; D000069285:Infliximab; D000077944:Alefacept; D000068879:Adalimumab; D000077339:Leflunomide; D001379:Azathioprine; D000068800:Etanercept; C472181:efalizumab